Werewolf Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $50.54M
- P/E (TTM)
- –
- Dividend yield
- –
About Werewolf Therapeutics
Pharmaceutical Preparations, SIC 2834
Werewolf Therapeutics is a clinical-stage biopharmaceutical company that designs and develops conditionally activated therapeutics to stimulate the immune system for treating cancer and other immune-mediated conditions. Using its proprietary PREDATOR platform, the company engineers molecules known as INDUKINE and INDUCER therapies, which function as inactive prodrugs systemically and activate selectively within the tumor microenvironment. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 therapy being evaluated in clinical trials for solid tumors, and WTX-330, an Interleukin-12 molecule being evaluated in clinical studies for advanced or metastatic solid tumors or lymphoma. The company also advances preclinical candidates and partners programs, including licensing rights for JZP898 to Jazz Pharmaceuticals Ireland Limited.
The company operates in the United States and pursues international patent protection for its platform technology, while licensing global development rights for select candidates. The provided report does not disclose physical store counts, specific office facilities, or its headquarters location.
Summary of the business section of Werewolf Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Werewolf Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 303 Wyman Street, Suite 300 02451
- Phone
- (617) 952-0555
- Website
- werewolftx.com
- Employees
- 39, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- HOWL
- Exchange
- Nasdaq
- IPO date
- Apr 30, 2021
- Shares outstanding
- 49M, Jul 27, 2026
- Public float
- $39.56M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1785530
- CUSIP
- 95075A107
- ISIN
- US95075A1079
- EIN
- 82-3523180
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel J. Hicklin | See Remarks, Director | 647,047 |
| Michael J. Urban | VP of Finance & Corp. Contr. | 5,284 |
| Steven H. Bloom | Chief Business Officer | – |
| Randi Isaacs | Chief Medical Officer | – |
| Timothy W. Trost | Chief Financial Officer | – |
| Chulani Karunatilake | Chief Technology Officer | – |
| Ellen Lubman | Chief Business Officer | – |
| Luke Evnin | Director | 0 |
| Meeta Chatterjee | Director | – |
| Briggs Morrison | Director | 15,523 |
| Alon Lazarus | Director | 1,235,917 |
| Michael A. Sherman | Director | – |
| Anil K. Singhal | Director | – |
| Michael B. Atkins | Director | 14,419 |
| RA Capital Nexus Fund II, L.P. | Director | 6,237,482 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 39 full-time employees, including a total of 15 employees with M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 22, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 6, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 6, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 15, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 7, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 30, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 27, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |